Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $5.2 million.

  • Akebia Therapeutics' Other Non-Current Liabilities rose 1089.49% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 1089.49%. This contributed to the annual value of $5.2 million for FY2024, which is 4147.44% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Other Non-Current Liabilities stood at $5.2 million, which was up 1089.49% from $14.2 million recorded in Q2 2025.
  • Akebia Therapeutics' Other Non-Current Liabilities' 5-year high stood at $85.4 million during Q2 2021, with a 5-year trough of $4.7 million in Q3 2024.
  • Its 5-year average for Other Non-Current Liabilities is $34.7 million, with a median of $15.7 million in 2022.
  • Per our database at Business Quant, Akebia Therapeutics' Other Non-Current Liabilities tumbled by 8867.03% in 2023 and then skyrocketed by 11656.25% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Other Non-Current Liabilities (Quarter) stood at $84.2 million in 2021, then tumbled by 81.34% to $15.7 million in 2022, then plummeted by 43.47% to $8.9 million in 2023, then crashed by 41.47% to $5.2 million in 2024, then rose by 0.81% to $5.2 million in 2025.
  • Its Other Non-Current Liabilities stands at $5.2 million for Q3 2025, versus $14.2 million for Q2 2025 and $7.2 million for Q1 2025.